MCID: CHR208
MIFTS: 22

Chromosome 17p Deletion

Categories: Rare diseases

Aliases & Classifications for Chromosome 17p Deletion

MalaCards integrated aliases for Chromosome 17p Deletion:

Name: Chromosome 17p Deletion 53
Chromosome 17p Deletion Syndrome 73
Loss of Chromosome 17p 73
Partial Monosomy 17p 53
17p Deletion 53
17p Monosomy 53
Deletion 17p 53
Monosomy 17p 53

Classifications:



External Ids:

Summaries for Chromosome 17p Deletion

MalaCards based summary : Chromosome 17p Deletion, also known as chromosome 17p deletion syndrome, is related to smith-magenis syndrome and medulloblastoma. An important gene associated with Chromosome 17p Deletion is MIR21 (MicroRNA 21). The drugs rituximab and Lenalidomide have been mentioned in the context of this disorder. Affiliated tissues include b cells and t cells.

Related Diseases for Chromosome 17p Deletion

Diseases related to Chromosome 17p Deletion via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 smith-magenis syndrome 11.3
2 medulloblastoma 10.0
3 lymphoma 9.9
4 leukemia, chronic lymphocytic 2 9.8
5 leukemia, chronic lymphocytic 9.8
6 b-cell lymphomas 9.8
7 diffuse large b-cell lymphoma 9.8
8 leukemia 9.8
9 lymphoblastic lymphoma 9.8
10 leukemia, b-cell, chronic 9.8

Graphical network of the top 20 diseases related to Chromosome 17p Deletion:



Diseases related to Chromosome 17p Deletion

Symptoms & Phenotypes for Chromosome 17p Deletion

Drugs & Therapeutics for Chromosome 17p Deletion

Drugs for Chromosome 17p Deletion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
2
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
3
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
4
Idelalisib Approved Phase 3,Phase 2 870281-82-6
5
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
6 Immunosuppressive Agents Phase 3,Phase 2
7 Anti-Infective Agents Phase 3,Phase 2
8 Antimetabolites Phase 3,Phase 2
9 Antimetabolites, Antineoplastic Phase 3,Phase 2
10 Alkylating Agents Phase 3,Phase 2
11 Angiogenesis Inhibitors Phase 3,Phase 2
12 Angiogenesis Modulating Agents Phase 3,Phase 2
13 Anti-Bacterial Agents Phase 3,Phase 2
14 Antibodies Phase 3,Phase 2
15 Immunoglobulins Phase 3,Phase 2
16 Antibodies, Monoclonal Phase 3,Phase 2
17 Antirheumatic Agents Phase 3,Phase 2
18 Bendamustine Hydrochloride Phase 3,Phase 2
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2
20 Receptors, Antigen, B-Cell Phase 3
21
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
22
alemtuzumab Approved, Investigational Phase 2 216503-57-0
23
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
24
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
25
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
26
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
27 Pomalidomide Approved Phase 2 19171-19-8
28
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
29
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
30 Ixazomib Approved, Investigational Phase 2 1072833-77-2
31
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
32 Dexamethasone acetate Phase 2 1177-87-3
33 glucocorticoids Phase 2
34
protease inhibitors Phase 2
35 Gastrointestinal Agents Phase 2
36 HIV Protease Inhibitors Phase 2
37 Hormone Antagonists Phase 2
38 Hormones Phase 2
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
40 Peripheral Nervous System Agents Phase 2
41 Antiemetics Phase 2
42 Anti-Inflammatory Agents Phase 2
43 BB 1101 Phase 2
44 Antiviral Agents Phase 2
45 Autonomic Agents Phase 2
46 Antineoplastic Agents, Hormonal Phase 2
47 Complement System Proteins Phase 2
48 Nitrogen Mustard Compounds Phase 2
49 Immunoglobulin G Phase 2
50 Protective Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
2 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy ( Recruiting NCT02980731 Phase 3 Venetoclax
3 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
4 A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor. Active, not recruiting NCT02756611 Phase 3 Venetoclax
5 A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy Active, not recruiting NCT01556776 Phase 3 lenalidomide;Placebo
6 Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia Active, not recruiting NCT01659021 Phase 3 Idelalisib;Ofatumumab
7 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Active, not recruiting NCT02005471 Phase 3 Bendamustine;Venetoclax;Rituximab
8 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Not yet recruiting NCT03406156 Phase 3 Obinutuzumab;Bendamustine;Venetoclax
9 OraTest in Combination With Visual Examination and Visual Examination Alone Terminated NCT00537199 Phase 3 OraTest
10 Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine Unknown status NCT01392079 Phase 2 Alemtuzumab
11 A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion Completed NCT01744691 Phase 2 Ibrutinib
12 Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) Completed NCT01745640 Phase 2 POMALIDOMIDE;Dexamethasone
13 Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia Completed NCT02015208 Phase 1, Phase 2 Ruxolitinib
14 Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies Completed NCT01966510 Phase 2
15 Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT02530515 Phase 2 Rituximab;Cyclophosphamide;Fludarabine monophosphate;Bendamustine;Lenalidomide
16 Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) Completed NCT01520922 Phase 2 Bendamustine
17 HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab Completed NCT00349349 Phase 2 ofatumumab
18 Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Recruiting NCT02337829 Phase 2 acalabrutinib;acalabrutinib
19 A Study Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17b Deletion Recruiting NCT02966756 Phase 2 Venetoclax
20 BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) Recruiting NCT02834364 Phase 2 Encorafenib;Binimetinib
21 A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion Active, not recruiting NCT01889186 Phase 2 ABT-199
22 Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL Active, not recruiting NCT01465334 Phase 2 Ofatumumab;High-Dose Methylprednisolone;Alemtuzumab
23 PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT01500733 Phase 2 PCI 32765
24 PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia Active, not recruiting NCT01589302 Phase 2 ibrutinib
25 Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma Active, not recruiting NCT02897830 Phase 2 Ixazomib;Lenalidomide;Dexamethasone
26 Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion Terminated NCT02044822 Phase 2 Idelalisib;Rituximab
27 Treatment Strategies for Children With Smith-Magenis Syndrome Completed NCT00506259 Phase 1 dTR Melatonin (NIH CC PDS);Melatonin CR
28 Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL) Unknown status NCT01675102
29 Natural History Study of Smith-Magenis Syndrome Recruiting NCT00013559
30 Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) Terminated NCT02273856

Search NIH Clinical Center for Chromosome 17p Deletion

Genetic Tests for Chromosome 17p Deletion

Anatomical Context for Chromosome 17p Deletion

MalaCards organs/tissues related to Chromosome 17p Deletion:

41
B Cells, T Cells

Publications for Chromosome 17p Deletion

Articles related to Chromosome 17p Deletion:

# Title Authors Year
1
Chromosome 17p deletion in a case of T-cell acute lymphoblastic lymphoma. ( 25195772 )
2014
2
Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia. ( 21570119 )
2011
3
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. ( 20393129 )
2010
4
Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma. ( 17982487 )
2008
5
Hedgehog checkpoints in medulloblastoma: the chromosome 17p deletion paradigm. ( 16290230 )
2005
6
Chromosome 17p deletion in human medulloblastoma: a missing checkpoint in the Hedgehog pathway. ( 15467454 )
2004
7
Prognostic implications of chromosome 17p deletions in human medulloblastomas. ( 8523074 )
1995

Variations for Chromosome 17p Deletion

Expression for Chromosome 17p Deletion

Search GEO for disease gene expression data for Chromosome 17p Deletion.

Pathways for Chromosome 17p Deletion

GO Terms for Chromosome 17p Deletion

Sources for Chromosome 17p Deletion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....